BIOMARIN PHARMACEUTICAL INC Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $12.60 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2025-02-24
- BIOMARIN PHARMACEUTICAL INC equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-12-31 was -$50.00K.
- BIOMARIN PHARMACEUTICAL INC equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-09-30 was $0.00.
- BIOMARIN PHARMACEUTICAL INC equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-06-30 was $50.00K.
- BIOMARIN PHARMACEUTICAL INC equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-03-31 was $12.60M.
- BIOMARIN PHARMACEUTICAL INC equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $12.60M.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$50.00K derived: sum of 2 quarters · filed 2025-02-24 | $0.00 derived: sum of 3 quarters · filed 2025-02-24 | $12.60M 10-K · filed 2025-02-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $50.00K derived: sum of 2 quarters · filed 2023-11-02 | $12.65M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $12.65M 10-Q · filed 2023-08-02 | ||
| 2023-03-31 | $12.60M 10-Q · filed 2024-10-31 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |